Swiss pharmaceutical company Novartis has filed a lawsuit against President Joe Biden's administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals. This move by Novartis could have significant repercussions on the negotiation process for the company's popular heart drug, Entresto, and its pricing under Medicare. Stay updated on market-moving news with TheFly and check out top-performing stocks on TipRanks.
Novartis Sues Biden Administration Over 340B Drug Discount Program
Swiss pharmaceutical giant Novartis has filed a lawsuit against the Biden administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration (HRSA) interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals.
The 340B Drug Discount Program is a federal program that was established in 1992 to provide discounted prescription drugs to low-income and uninsured patients. Hospitals that participate in the program are required to pass along the discounts they receive from drug manufacturers to patients.
Novartis argues that the HRSA has misinterpreted the 340B law by requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients. The company says that this interpretation of the law has led to "significant overpayments" to hospitals and that it has been forced to subsidize the program with its own profits.
The lawsuit could have significant repercussions on the negotiation process for Novartis's popular heart drug, Entresto. The drug is currently covered under Medicare Part D, and Novartis is seeking to change the payment terms for Entresto in order to increase its profits. The lawsuit could delay or prevent Novartis from making these changes, which could impact the price of Entresto for Medicare beneficiaries.
Background
The 340B Drug Discount Program was created as part of the Omnibus Budget Reconciliation Act of 1990. The program was originally designed to help hospitals that serve a disproportionate share of low-income and uninsured patients. The program has since been expanded to include a wider range of hospitals, including many that do not serve a disproportionate share of low-income and uninsured patients.
In 2010, the Affordable Care Act made significant changes to the 340B program. The changes included adding new eligibility requirements for hospitals and increasing the discounts that drug manufacturers are required to provide.
Top 5 FAQs
1. What is the 340B Drug Discount Program?
The 340B Drug Discount Program is a federal program that requires drug manufacturers to provide discounts to hospitals that serve a disproportionate share of low-income and uninsured patients. The program is designed to help these hospitals provide affordable prescription drugs to their patients.
2. What is Novartis's lawsuit about?
Novartis is suing the Biden administration over the HRSA's interpretation of the 340B law. Novartis argues that the HRSA is requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients.
3. What could the lawsuit mean for Novartis?
The lawsuit could delay or prevent Novartis from making changes to the payment terms for its popular heart drug, Entresto. This could impact the price of Entresto for Medicare beneficiaries.
4. What could the lawsuit mean for the 340B program?
The lawsuit could have a significant impact on the 340B program. If Novartis is successful in its lawsuit, it could lead to changes in the way that the program is administered. This could make it more difficult for hospitals to participate in the program or could reduce the discounts that hospitals receive from drug manufacturers.
5. What is the future of the 340B program?
The future of the 340B program is uncertain. The program has been the subject of ongoing debate, with some stakeholders arguing that it is too costly and that it does not effectively target low-income and uninsured patients. However, the program remains popular with hospitals and patient advocates, and it is likely to continue to be a source of controversy in the years to come.
On World Red Cross and Red Crescent Day, observed on May 8th to honor the birth of ICRC founder Henry Dunant, the IFRC reported that 28 volunteers have lost their lives while providing aid and assistance to communities in need. This year's theme, "Keeping Humanity Alive," recognizes the selfless and courageous work of these humanitarian workers, who often face great risks in severe and dangerous situations. The day serves as a reminder of their sacrifices and the ongoing need for their vital services. In related sports news, a veteran batter has been called in to replace injured player Devdutt Padikkal on the RCB team.
The Reserve Bank of India (RBI) has implemented a new framework for formulating regulations, with an aim to promote transparency and stakeholder engagement. Under the new process, the RBI will publish draft regulations on its official website and allow stakeholders 21 days to provide feedback. The framework also mandates an impact analysis before finalizing any regulation and periodic reviews to ensure its relevance. However, certain regulations may be exempted from the framework in cases where confidentiality or public interest is at stake.
As the stock market opens today, investors will be keeping a close eye on the actions of the Reserve Bank of India and the Supreme Court. RBI's announcement of a ₹50,000 crore OMO (open market operation) as well as the Supreme Court's hearing on the highly debated GST case involving online gaming will significantly impact market movement. Stay updated on these crucial triggers and their effects on stock prices with Stock In News.
Ather Energy, the electric vehicle startup, recently listed at a premium of 2.18% and investors are eager to know the company's future plans. In an exclusive conversation with Zee Business, Ather Energy's co-founder, ED & CTO, Swapnil Jain and CFO, Sohil Parekh reveal the company's future strategies and investments. Ather Energy plans to use the funds raised from its IPO for expanding its manufacturing facilities, R&D efforts, and increasing its footprint in the Indian electric vehicle market. Don't miss this insightful interview for a deep dive into Ather Energy's plans and vision.
After a successful initial public offering, electric two-wheeler maker Ather Energy Ltd listed its shares on the BSE with a premium of 2% over the issue price of Rs 321. However, analysts are cautioning risk-taking investors to hold their positions, citing intense competition and capital risks in the electric two-wheeler market. With a high growth-high competition-high cash burning segment, volatility and risk are expected for short- to medium-term investments in Ather Energy. The company's IPO was subscribed 1.43 times on the closing day, and its market valuation currently stands at Rs 12,110.53 crore.
After moving to a larger space in November, Beyond Boundaries Therapy and Wellness is inviting the public to a free event this Saturday, May 3, to showcase their new location. The clinic will be offering various occupational, physical, and speech therapy services, as well as wellness services for the whole family. Visitors can also participate in fun activities while learning more about the clinic's programs. President and CEO, LaDonna Bannach, hopes the new space will make it easier for families to access different areas of wellness.
The Minister of Investment, Trade and Industry, Datuk Seri Tengku Zafrul Abdul Aziz announced that from tomorrow, the Ministry of Investment, Trade and Industry (Miti) will have full control over Non-Preferential Certificates of Origin (NPCO) for exports to the US. This is to prevent other countries from using Malaysia as a transhipment point to circumvent US tariffs. The government is also committed to upholding the integrity of international trade practices and any attempts to fake declarations will be punished. This comes after reports of China-based brokers rerouting goods through Malaysia and falsely labelling them as Malaysian to avoid US tariffs on Chinese imports.
Mahindra, a leading Indian automotive brand, has been a major success in the SUV market. Its popular Thar lineup, known for its sturdy design and off-roading capabilities, is now set for some changes. According to industry sources, the brand will be phasing out eight variants of the Thar to streamline its lineup. This includes the entry-level AX AWD variant and the open differential AWD LX trims. With the changes, the Thar will now be available in 19 variants ranging from Rs 13.87 lakh to Rs 21.32 lakh.
A Samsung store in Singapore's AMK Hub caught fire this morning, adding to the company's recent string of product-related mishaps. Luckily, the fire was quickly put out by sprinklers and no one was injured. The cause of the fire is still under investigation, but it certainly doesn't bode well for Samsung as they prepare to unveil their highly anticipated Galaxy S8 in New York City on Wednesday. Stay tuned to see if the company can bounce back from this latest setback.
In a surprise announcement, Warren Buffett, the renowned 'Oracle of Omaha', revealed that he will be stepping down as CEO of Berkshire Hathaway and passing the reins to Greg Abel at the end of 2025. The decision, made during the company's annual shareholders meeting, sent shockwaves through the business world, with many global leaders expressing their admiration and well-wishes for Buffett's retirement. However, they also have confidence in Abel to continue the success of the renowned investment company.